{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:41:58Z","timestamp":1794062518221,"version":"4.8.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"52","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21nf0101636h0001"],"award-info":[{"award-number":["21nf0101636h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.vaccine.2022.10.088","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:31:05Z","timestamp":1667781065000},"page":"7622-7630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan"],"prefix":"10.1016","volume":"40","author":[{"given":"Yoshinori","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Iwagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Michihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yasunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.10.088_b0005","unstructured":"Our World in Data. Coronavirus Pandemic (COVID-19). 2022. [Available from: https:\/\/ourworldindata.org\/coronavirus#explore-the-global-situation."},{"issue":"5","key":"10.1016\/j.vaccine.2022.10.088_b0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.vaccine.2022.10.088_b0015","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.10.088_b0020","first-page":"100442","article-title":"Safety monitoring of COVID-19 vaccines in Japan","volume":"23","author":"Yamaguchi","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"issue":"12","key":"10.1016\/j.vaccine.2022.10.088_b0025","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.vaccine.2022.10.088_b0030","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for Adverse Events After COVID-19 mRNA Vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2022.10.088_b0035","doi-asserted-by":"crossref","unstructured":"Farrington P, Whitaker H, Weldeselassie YG. Self-Controlled Case Series Studies: A Modelling Guide with R. Boca Raton, FL: Chapman and Hall\/CRC; 2018.","DOI":"10.1201\/9780429491313"},{"key":"10.1016\/j.vaccine.2022.10.088_b0040","doi-asserted-by":"crossref","unstructured":"Li X, Raventos B, Roel E, Pistillo A, Martinez-Hernandez E, Delmestri A, et al. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. BMJ. 2022;376:e068373.","DOI":"10.1136\/bmj-2021-068373"},{"issue":"6","key":"10.1016\/j.vaccine.2022.10.088_b0045","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.10.088_b0050","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/aje\/kwq099","article-title":"A simple approach to the estimation of incidence rate difference","volume":"172","author":"Xu","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"10","key":"10.1016\/j.vaccine.2022.10.088_b0055","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/sim.9325","article-title":"A modified self-controlled case series method for event-dependent exposures and high event-related mortality, with application to COVID-19 vaccine safety","volume":"41","author":"Ghebremichael\u2010Weldeselassie","year":"2022","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2022.10.088_b0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/biostatistics\/kxn013","article-title":"Case series analysis for censored, perturbed, or curtailed post-event exposures","volume":"10","author":"Farrington","year":"2009","journal-title":"Biostatistics"},{"issue":"1","key":"10.1016\/j.vaccine.2022.10.088_b0065","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jama.2021.21699","article-title":"Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older","volume":"327","author":"Jabagi","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2022.10.088_b0070","doi-asserted-by":"crossref","first-page":"101504","DOI":"10.1016\/j.eclinm.2022.101504","article-title":"Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: A self-controlled case series study","volume":"50","author":"Chui","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2022.10.088_b0075","doi-asserted-by":"crossref","first-page":"e932946","DOI":"10.12659\/AJCR.932946","article-title":"A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine","volume":"22","author":"Al-Maqbali","year":"2021","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.vaccine.2022.10.088_b0080","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12874-017-0457-7","article-title":"A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies","volume":"18","author":"Takeuchi","year":"2018","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.10.088_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0258(19990115)18:1<1::AID-SIM961>3.0.CO;2-L","article-title":"A unified approach to the analysis of case-distribution (case-only) studies","volume":"18","author":"Greenland","year":"1999","journal-title":"Stat Med"},{"issue":"43","key":"10.1016\/j.vaccine.2022.10.088_b0090","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.15585\/mmwr.mm7043e2","article-title":"COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021","volume":"70","author":"Xu","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"10.1016\/j.vaccine.2022.10.088_b0095","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S1473-3099(07)70236-0","article-title":"Mortality benefits of influenza vaccination in elderly people: an ongoing controversy","volume":"7","author":"Simonsen","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2022.10.088_b0100","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ije\/dyi275","article-title":"Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors","volume":"35","author":"Jackson","year":"2006","journal-title":"Int J Epidemiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:20:25Z","timestamp":1759404025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22013706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":20,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0264410X22013706"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.088","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}